Personalized vaccine for advanced esophageal cancer after treatment
Part of Cancer, Digestive system clinical trials.
This trial tests a personalized vaccine made from your tumor's unique markers (neoantigens) to help prevent your advanced esophageal cancer from coming back. It's for people who have already completed strong treatment and are currently cancer-free, but have a high risk of recurrence.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have advanced esophageal cancer that could not be removed by surgery, and you have already finished a strong treatment plan (chemotherapy with radiation, or radiation alone).
- After your last treatment, a scan shows no signs of the cancer coming back or spreading.
- You can provide a fresh sample of your tumor tissue.
- You have not had a fistula (an abnormal connection) caused by the tumor, and you are not at high risk for bleeding or a hole in the esophagus.
- You are generally in good health (able to do daily activities without help) and your major organs work well.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of low-dose radiation and immunotherapy for people with advanced esophageal cancer that cannot be surgically removed. The goal is to see if this approach is safe and effective after initial treatment.
This trial tests whether combining a new immunotherapy drug (adebrelimab) with standard chemotherapy can help shrink borderline resectable esophageal squamous cell carcinoma before surgery. The goal is to make tumors easier to remove and improve survival.
This trial tests whether giving immunotherapy after surgery can help prevent cancer from returning in patients with esophageal squamous cell carcinoma. It is for people who have already received chemotherapy and immunotherapy before surgery and had surgery to remove the cancer, but still had some cancer cells found in the removed tissue.
This trial tests whether adding two immunotherapy drugs to standard chemotherapy and radiation before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a certain type of esophageal cancer that can be removed with surgery.
This trial tests giving immunotherapy (PD-1 inhibitors) along with local treatments like radiation or surgery at different times for patients whose esophageal cancer has spread to only a few spots. The goal is to see the best timing for these combined treatments.
This trial tests whether adding a new immunotherapy drug (adebrelimab) to standard chemotherapy and radiation improves outcomes for patients with esophageal squamous cell carcinoma before surgery. The goal is to shrink the tumor and improve survival.
Hear when a new Immune Checkpoint Inhibitors (ICIs) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.